

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17679 (BOT)	SERIAL NO.: 10/789,180
APPLICANT: Catherine Turkel et al.	TITLE: METHODS FOR TREATING PAIN AND FOR TREATING A MEDICATION OVERUSE DISORDER
FILING DATE: February 26, 2004	GROUP:

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
17H	AA	10/194,805		Donovan, Stephen			7/11/2002
	AB	10/423,380		Ackerman, Alan H.			4/25/2003
	AC	10/429,069		Voet, Martin A.			5/2/2003
	AD	10/630,587		Aoki et al.			7/29/2003
	AE	10/731,973		First, Eric R.			12/9/2003
	AF	10/752,869		First, Eric R.			1/6/2004
	AG	60/418,789		Katz, Howard			10/15/2002
	AH	2003 0224019	12/4/2003	Christopher O'Brien			
	AI	5,437,291	8/1/1995	Pasricha et al.			
	AJ	5,670,484	9/23/1997	William J. Binder			
	AK	5,714,468	2/3/1998	William J. Binder			
	AL	5,766,605	6/16/1998	Sanders et al.			
	AM	5,989,545	11/23/1999	Foster et al.			
	AN	6,063,768	5/16/2000	Eric R. First			
	AO	6,139,845	10/31/2000	Stephen Donovan			
	AP	6,299,893	10/9/2001	Schwartz et al.			
	AQ	6,306,423	10/23/2001	Donovan et al.			
	AR	6,312,708	11/6/2001	Stephen Donovan			
	AS	6,358,917	3/19/2002	Carruthers et al.			
	AT	6,423,319	7/23/2002	Brooks et al.			
	AU	6,447,787	9/10/2002	Gassner et al.			
	AV	6,458,365	10/1/2002	Aoki et al.			
	AW	6,464,986	10/15/2002	Aoki et al.			
	AX	6,623,742	9/23/2003	Martin A. Voet			

EXAMINER

Vanessa Ford

DATE CONSIDERED

9/10/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17679 (BOT)	SERIAL NO.: 10/789,180
APPLICANT: Catherine Turkel et al.	TITLE: METHODS FOR TREATING PAIN AND FOR TREATING A MEDICATION OVERUSE DISORDER
FILING DATE: February 26, 2004	GROUP:

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
	BA	DE 101 50 415	5/15/2003	Germany			N
		A1					
	BK	WO 03/01 1333	2/13/2003	PCT			Y

OTHER ART

(Including Author, Title, Date, Pertinent Pages, etc.)

CA	Aoki K., et al, <i>Mechanisms of the antinociceptive effect of subcutaneous Botox: Inhibition of peripheral and central nociceptive processing</i> , Cephalalgia 2003 Sep;23(7):649
CB	Aoki, K., et al., <i>Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions</i> , Eur J. Neurol 2001: (suppl 5); 21-29
CC	Aoki, K., <i>Physiology and pharmacology of therapeutic botulinum neurotoxins</i> , in Kreyden, O., editor, <i>Hyperhydrosis and botulinum toxin in dermatology</i> , Basel, Karger; 2002; 30: pages 107-116, at 109-110
CD	Bhattacharya K., et al., <i>Novel uses of botulinum toxin type A: two case reports</i> , Mov Disord 2000; 15(Suppl 2):51-52
CE	Bigalke H., et al., <i>Botulinum A Neurotoxin Inhibits Non-Cholinergic Synaptic Transmission in Mouse Spinal Cord Neurons in Culture</i> , Brain Research 360;318-324:1985
CF	Bigalke H., et al., <i>Tetanus Toxin and Botulinum A Toxin Inhibit Release and Uptake of Various Transmitters, as Studied with Particulate Preparations From Rat Brain and Spinal Cord</i> , Naunyn-Schmiedeberg's Arch Pharmacol 316;244-251:1981
CG	Binz T. et al., <i>The Complete Sequence of Botulinum Neurotoxin Type A and Comparison with Other Clostridial Neurotoxins</i> , J Biological Chemistry 265(16):9153-9158:1990
CH	Blugerman G., et al., <i>Multiple eccrine hidrocystomas: A new therapeutic option with botulinum toxin</i> , Dermatol Surg 2003 May;29(5):557-9



EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17679 (BOT)	SERIAL NO.: 10/789,180
APPLICANT: Catherine Turkel et al.	TITLE: METHODS FOR TREATING PAIN AND FOR TREATING A MEDICATION OVERUSE DISORDER
FILING DATE: February 26, 2004	GROUP:

	CI	Brem, H., et al, <i>Placebo-Controlled Trial of Safety and Efficacy of Intraoperative Controlled Delivery by Biodegradable Polymers of Chemotherapy for Recurrent Gliomas</i> , Lancet 345;1008-1012:1995
	CJ	Brin, M., et al., <i>Botulinum toxin type A: pharmacology</i> , in Mayer N., editor, <i>Spasticity: etiology, evaluation, management and the role of botulinum toxin</i> , 2002; pages 110-124, at 112-113
	CK	Bushara K., <i>Botulinum toxin and rhinorrhea</i> , Otolaryngol Head Neck Surg 1996;114(3):507
	CL	Cui, M., et al., <i>Mechanisms of the antinociceptive effect of subcutaneous BOTOX®: inhibition of peripheral and central nociceptive processing</i> , Naunyn Schmiedebergs Arch Pharmacol 2002; 365 (supp 2): R17
	CM	Dabrowski et al.; <i>Botulinum toxin as a novel treatment for self mutilation in Lesch-Nyhan syndrome</i> , Ann Neurol 2002 Sep;52(3 Supp 1):S157
	CN	Duggan et al.; <i>A surbey of Botulinum neurotoxin substrate expression in cells</i> ; Mov Disord, 10(3):376:1995
	CO	Fung L. K. et al., <i>Pharmacokinetics of Interstitial Delivery of Carmustine 4-Hydroperoxycyclophosphamide and Paclitaxel From a Biodegradable Polymer Implant in the Monkey Brain</i> , Cancer Research 58;672-684:1998
	CP	Gonelle-Gispert et al.; <i>snap-25a and -25b isoforms are both expressed in insulin-secreting cells and can function in insulin secretion</i> ; Biochem J 1;339 (pt 1):159-65:1999
	CQ	Guyton A.C. et al., <i>Textbook of Medical Physiology</i> , W.B. Saunders Company 1996, ninth edition; 686-688
	CR	Habermann E., et al., <i>Tetanus Toxin and Botulinum A and C Neurotoxins Inhibit Noradrenaline Release From Cultured Mouse Brain</i> , J Neurochem 51(2);522-527:1988
	CS	Habermann E., <i>Inhibition by Tetanus and Botulinum A Toxin of the release of [³H]Noradrenaline and [³H]GABA From Rat Brain Homogenate</i> , Experientia 44;224-226: 1988
	CT	Habermann, I-Labeled Neurotoxin from Clostridium Botulinum A: Preparation, Binding to Synaptosomes and Ascent to the Spinal Cord; Nauyn-Schmiedeberg's Arch. Pharmacol. 1974; 281, 47-56,

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17679 (BOT)	SERIAL NO.: 10/789,180
APPLICANT: Catherine Turkel et al.	TITLE: METHODS FOR TREATING PAIN AND FOR TREATING A MEDICATION OVERUSE DISORDER
FILING DATE: February 26, 2004	GROUP:

CU	Harrison's Principles of Internal Medicine (1998), edited by Anthony Fauci et al., 14 th edition, published by McGraw Hill
CV	Heckmann M., et al., Botulinum toxin type A injection in the treatment of lichen simplex: An open pilot study, J Am Acad Dermatol 2002 Apr;46(4):617-9
CW	Jacks, L., et al., Idiopathic toe walking: Treatment with botulinum toxin A injection, Dev Med Child Neurol 2002;44(Suppl 91):6, and foot dystonia (Rogers J., et al., Injections of botulinum toxin A in foot dystonia, Neurology 1993 Apr;43(4 Suppl 2
CX	Jahanshahi M., et al., Psychological functioning before and after treatment of torticollis with botulinum toxin, J Neurol Neurosurg Psychiatry 1992; 55(3): 229-231
CY	Jankovic J. et al., Therapy With Botulinum Toxin, Marcel Dekker, Inc., (1994), page 5, 150
CZ	Jost W., Ten years' experience with botulinum toxin in anal fissure, Int J Colorectal Dis 2002 Sep;17(5):298-302
CAA	Katsambas A., et al., Cutaneous diseases of the foot: Unapproved treatments, Clin Dermatol 2002 Nov-Dec;20(6):689-699
CBB	Li Y, et al., Sensory and motor denervation influences epidermal thickness in rat foot glabrous skin, Exp Neurol 1997;147:452-462 (see page 459)
CCC	Marjama-Lyons, J., et al., Tremor-Predominant Parkinson's Disease, Drugs & Aging 16(4);273-278:2000
CDD	Moyer E et al., Botulinum Toxin Type B: Experimental and Clinical Experience, being chapter 6, pages 71-85 of "Therapy With Botulinum Toxin", edited by Jankovic, J. et al. (1994), Marcel Dekker, Inc.
CEE	Murry T., et al., Spasmodic dysphonia; emotional status and botulinum toxin treatment, Arch Otolaryngol 1994 Mar; 120(3): 310-316
CFF	Naumann et al; Botulinum toxin type A in the treatment of focal, axillary and palmar hyperhidrosis and other hyperhidrotic conditions; European J. Neurology 6 (Supp 4): S111-S1150:1999
CGG	Pearce, L.B., Pharmacologic Characterization of Botulinum Toxin For Basic Science and Medicine, Toxicon 35(9);1373-1412 at 1393
CHH	Ragona et al.; Management of Parotid Sialoceles With Botulinum Toxin; The Laryngoscope 109:1344-1346:1999
CII	Sanchez-Prieto, J., et al., Botulinum Toxin A Blocks Glutamate Exocytosis From Guinea Pig Cerebral Cortical Synaptosomes, Eur J. Biochem 165;675-681:1897


EXAMINER

DATE CONSIDERED


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17679 (BOT)	SERIAL NO.: 10/789,180
APPLICANT: Catherine Turkel et al.	TITLE: METHODS FOR TREATING PAIN AND FOR TREATING A MEDICATION OVERUSE DISORDER
FILING DATE: February 26, 2004	GROUP:

	CJJ	Schantz, E.J., et al, <i>Properties and use of Botulinum toxin and Other Microbial Neurotoxins in Medicine</i> , Microbiol Rev. 56;80-99:1992
	CKK	Sevim, S., et al., <i>Botulinum toxin-A therapy for palmar and plantar hyperhidrosis</i> , Acta Neurol Belg 2002 Dec;102(4):167-70
	CLL	Singh, <i>Critical Aspects of Bacterial Protein Toxins</i> , pages 63-84 (chapter 4) of Natural Toxins II, edited by B.R. Singh et al., Plenum Press, New York (1976
	CMM	Suputtitada, A., <i>Local botulinum toxin type A injections in the treatment of spastic toes</i> , Am J Phys Med Rehabil 2002 Oct;81(10):770-5
	CNN	Weigand et al.; I-Labelled Botulinum A Neurotoxin: Pharmacokinetics in Cats after Intramuscular Injection; <i>Nauny-Schmiedeberg's Arch. Pharmacol.</i> 1976; 292, 161-165
	COO	Woolf C. et al., <i>Neuropathic Pain: Aetiology, Symptoms, Mechanisms, and Management</i> , Lancet 1999; 353: 1959-64

EXAMINER



DATE CONSIDERED

9/10/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.